Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;24(8):1604-1617.
doi: 10.1016/j.gim.2022.04.020. Epub 2022 May 16.

Can polygenic risk scores contribute to cost-effective cancer screening? A systematic review

Padraig Dixon  1 , Edna Keeney  2 , Jenny C Taylor  3 , Sarah Wordsworth  4 , Richard M Martin  5
Affiliations

Can polygenic risk scores contribute to cost-effective cancer screening? A systematic review

Padraig Dixon et al. Genet Med. 2022 Aug.

Abstract

Purpose: Polygenic risk influences susceptibility to cancer. We assessed whether polygenic risk scores could be used in conjunction with other predictors of future disease status in cost-effective risk-stratified screening for cancer.

Methods: We undertook a systematic review of papers that evaluated the cost-effectiveness of screening interventions informed by polygenic risk scores compared with more conventional screening modalities. We included papers reporting cost-effectiveness outcomes with no restriction on type of cancer or form of polygenic risk modeled. We evaluated studies using the Quality of Health Economic Studies checklist.

Results: A total of 10 studies were included in the review, which investigated 3 cancers: prostate (n = 5), colorectal (n = 3), and breast (n = 2). Of the 10 papers, 9 scored highly (score >75 on a 0-100 scale) when assessed using the quality checklist. Of the 10 studies, 8 concluded that polygenic risk-informed cancer screening was likely to be more cost-effective than alternatives.

Conclusion: Despite the positive conclusions of the included studies, it is unclear if polygenic risk stratification will contribute to cost-effective cancer screening given the absence of robust evidence on the costs of polygenic risk stratification, the effects of differential ancestry, potential downstream economic sequalae, and how large volumes of polygenic risk data would be collected and used.

Keywords: Cancer; Cost-effectiveness; Polygenic risk scores; Screening; Systematic review.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest E.K. reports personal fees from Novartis Pharma AG, Roche, Pfizer Inc, and Bristol-Myers Squibb outside the submitted work. R.M.M. has received other funding from Cancer Research UK to evaluate the long-term effectiveness and cost-effectiveness of population-based screening and treatment for prostate cancer: the CAP (Cluster randomised trial of PSA testing for prostate cancer) and ProtecT randomized controlled trials. He has also received funding from National Institute for Health Research Bristol Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol outside the submitted work. All other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Identification of studies.
EED, Economic Evaluation Database; HTA, Health Technology Assessment; NICE, National Institute for Health and Care Excellence.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Raoof S, Kennedy CJ, Wallach DA, Bitton A, Green RC. Molecular cancer screening: in search of evidence. Nat Med. 2021;27(7):1139–1142. doi: 10.1038/s41591-021-01431-5. - DOI - PubMed
    1. Manchanda R, Loggenberg K, Sanderson S, et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst. 2014;107(1):379. doi: 10.1093/jnci/dju379. - DOI - PMC - PubMed
    1. Easton D, Pashayan N, Pharoah P. In: Annual Report of the Chief Medical Officer 2017—Generation Genome. Davies S, editor. Department of Health; 2017. Risk-stratified cancer screening.
    1. Sinicrope FA. Lynch syndrome-associated colorectal cancer. N Engl J Med. 2018;379(8):764–773. doi: 10.1056/NEJMcp1714533. - DOI - PubMed
    1. Polygenic Risk Score Task Force of the International Common Disease Alliance. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps. Nat Med. 2021;27(11):1876–1884. doi: 10.1038/s41591-021-01549-6. - DOI - PubMed

Publication types